Skip to main content
Premium Trial:

Request an Annual Quote

Bielefeld University's CeBiTec Purchases New Hardware from Active Motif's TimeLogic

Premium

TimeLogic, an Active Motif subsidiary, said this week that the Center for Biotechnology (CeBiTec) at Bielefeld University has added the latest version of its J-series field programmable gate array hardware to its suite of computational tools.

This purchase adds to an existing DeCypher system at CeBiTec that supports research into gene and protein functions. TimeLogic’s DeCypher systems use a combination of field programmable gate array-based PCIe accelerator cards and servers to run implementations of Blast, Smith-Waterman, hidden Markov model, and gene modeling algorithms.

Michael Murray, the sales & marketing manager for TimeLogic products at Active Motif, said in a statement that the newly added hardware "will run Tera-BLAST, our accelerated BLAST implementation, many hundreds of times faster than the software-only version." It will also speed up analysis workflows for things like genome annotation, comparative genomics, and metagenomics.

The financial details of the purchase were not disclosed.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.